Denise Goode, as the Chief Executive of QED Life Sciences Limited, leverages over 25 years of extensive experience in pharmaceuticals, combining strategic insight with scientific acumen to drive innovation and growth within the life sciences sector. Since founding QED in 2014, Denise has positioned the...
Denise Goode, as the Chief Executive of QED Life Sciences Limited, leverages over 25 years of extensive experience in pharmaceuticals, combining strategic insight with scientific acumen to drive innovation and growth within the life sciences sector. Since founding QED in 2014, Denise has positioned the company as a pivotal player in facilitating connections between client companies and the broader life science community. Her role involves interfacing with senior executives and technical leaders across global pharmaceutical companies, ensuring that innovative ideas and disruptive strategies are effectively communicated and implemented.
Under Denise's leadership, QED has embarked on key projects that emphasize business innovation and strategic direction, focusing on areas such as clinical development, market access, and biotechnology. Her expertise in financial analysis and business strategy has been instrumental in guiding client companies through complex challenges, enabling them to navigate the intricacies of the life sciences landscape successfully. As an independent strategic advisor, Denise also mentors CEOs and senior leaders, fostering a culture of leadership and excellence within the industry.
In addition to her role at QED, Denise serves as a Non-Executive Director for ABLIVA AB, where she chairs the Remuneration Committee and contributes to the Audit & Risk Committee at Alligator Bioscience AB. Her multifaceted experience not only enhances her strategic vision but also underscores her commitment to advancing the life sciences field through collaboration and innovative thinking. With a strong foundation in management and consulting, Denise Goode continues to be a driving force in shaping the future of pharmaceuticals and biotechnology.
